CTNM
Contineum Therapeutics, Inc.
15.24
2 x 11.59
2 x 19.57
bid
ask
-
1.15
7.02%
2 @ 04:00 PM
15.23 -0.01 (0.07%)
| Ytd | 33.33% | |
| 1y | 295.84% |
15.14
day range
16.39
3.72
52 week range
16.91
| Open | 16.37 | Prev Close | 16.39 | Low | 15.14 | High | 16.39 | Mkt Cap | 569.77M |
| Vol | 313.50K | Avg Vol | 305.81K | EPS | -1.94 | P/E | N/A | Forward P/E | -7.68 |
| Beta | N/A | Short Ratio | 13.66 | Inst. Own | 72.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 13.14 | 200-d Avg | 12.59 | 1yr Est | 29.25 |
| Income Statement | |||
| Operating Expenses | 16.90M | ||
| Research and Development Expense | 11.65M | ||
| Selling, General and Administrative Expense | 5.26M | ||
| Operating Income | -16.90M | ||
| Net Income | -14.46M | ||
| Net Income Common Stock | -14.46M | ||
| Net Income Common Stock (USD) | -14.46M | ||
| Consolidated Income | -14.46M | ||
| Earnings per Basic Share | -0.39 | ||
| Earnings per Basic Share (USD) | -0.39 | ||
| Earnings per Diluted Share | -0.39 | ||
| Earning Before Interest & Taxes (EBIT) | -14.46M | ||
| Earning Before Interest & Taxes (USD) | -14.46M | ||
| Weighted Average Shares | 37.34M | ||
| Weighted Average Shares Diluted | 37.34M | ||
| Balance Sheet | |||
| Cash and Equivalents | 20.16M | ||
| Cash and Equivalents (USD) | 20.16M | ||
| Investments | 226.17M | ||
| Investments Current | 226.17M | ||
| Current Assets | 252.96M | ||
| Property, Plant & Equipment Net | 8.07M | ||
| Total Assets | 261.35M | ||
| Debt Current | 2.30M | ||
| Total Debt | 6.95M | ||
| Current Liabilities | 6.66M | ||
| Debt Non-Current | 4.65M | ||
| Total Liabilities | 11.31M | ||
| Accumulated Retained Earnings (Deficit) | -191.84M | ||
| Accumulated Other Comprehensive Income | -253.00K | ||
| Shareholders Equity | 250.04M | ||
| Shareholders Equity (USD) | 250.04M | ||
| Assets Non-Current | 8.39M | ||
| Total Debt (USD) | 6.95M | ||
| Liabilities Non-Current | 4.65M | ||
| Trade and Non-Trade Payables | 1.50M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 707.00K | ||
| Net Cash Flow from Financing | 129.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -55.44M | ||
| Capital Expenditure | -312.00K | ||
| Issuance (Purchase) of Equity Shares | 198.00K | ||
| Net Cash Flow from Investing | -39.31M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -39.00M | ||
| Net Cash Flow from Operations | -16.27M | ||
| Share Based Compensation | 3.82M | ||